Vermillion, Inc. (NASDAQ:VRML) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.12 and traded as high as $0.89. Vermillion shares last traded at $0.89, with a volume of 5,419 shares trading hands.
Separately, ValuEngine upgraded shares of Vermillion from a “hold” rating to a “buy” rating in a research report on Wednesday, May 15th.
The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.24 and a current ratio of 2.27. The business’s 50-day moving average is $1.11.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Magnus Financial Group LLC acquired a new position in Vermillion in the 1st quarter valued at approximately $35,000. B. Riley Wealth Management Inc. increased its position in Vermillion by 38.4% in the 4th quarter. B. Riley Wealth Management Inc. now owns 182,245 shares of the company’s stock valued at $55,000 after acquiring an additional 50,545 shares during the period. Vanguard Group Inc. increased its position in Vermillion by 16.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,452,612 shares of the company’s stock valued at $1,031,000 after acquiring an additional 209,600 shares during the period. Finally, Birchview Capital LP increased its position in Vermillion by 0.4% in the 1st quarter. Birchview Capital LP now owns 2,121,933 shares of the company’s stock valued at $2,440,000 after acquiring an additional 8,000 shares during the period. Hedge funds and other institutional investors own 20.45% of the company’s stock.
About Vermillion (NASDAQ:VRML)
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
Featured Story: Cost of Debt
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.